Japan Circulation Society 2017: Orsiro Drug-Eluting Coronary Stent Convinces in BIOFLOW-IV Study
Non-Inferiority of Orsiro vs. Xience Proven with Target Vessel Failure of 3.5% and 4.2%, respectively
BIOTRONIK, a leading manufacturer of cardio- and endovascular technology, presented 12-month results of the BIOFLOW-IV multi-center clinical study at this year’s Japan Circulation Society congress. The BIOFLOW-IV study is a prospective multi-center, randomized controlled trial with a five-year follow-up. The positive results of this study support the submission for Japanese market approval.
The BIOFLOW-IV study included 579 patients from 12 Japanese sites and 34 non-Japanese sites. Patients with de novo coronary lesions were randomized in a 2:1 ratio (Orsiro: Xience). Non-inferiority of the primary endpoint of target vessel failure was confirmed at 3.5% in the Orsiro arm and 4.2% in the Xience arm respectively, at the 12-month mark (p-value: 0.0001).
Dr. Shigeru Saito, Director of Cardiology and Catheterization Laboratories, and Vice President at the Shonan Kamakura Hospital, Kanagawa, Japan, commented: "In the BIOFLOW-IV study, the excellent efficacy and safety profiles of Orsiro was confirmed. This outcome is consistent with the outcomes of other Orsiro clinical studies conducted outside Japan.” The coordinating clinical investigator of this study continued: “I look forward to seeing Orsiro obtain premarket approval from the Japanese government and being made available to Japanese patients."
Widely used in Europe, Orsiro has consistently displayed its effectiveness and safety in numerous clinical trials, enrolling more than 32,500 patients to date. The BIOSCIENCE trial, published in The Lancet2, proved most similar to the BIOFLOW-IV study; it confirmed non-inferiority of the Orsiro to the Xience stent family in a patient group reflective of a routine clinical practice.
Dr. Kiyotaka Iwasaki, Cooperative Major in Advanced Biomedical Sciences, Graduate School of Advanced Science and Engineering, Waseda University (TWIns), Japan, said: "Ultra-thin 60 μm Orsiro DES had no stent fracture in an accelerated 10-year durability testing performed at our institute. This device has potential to provide more benefits to long-term patients’ safety."
"This clinical data represents a significant milestone in helping to bring this product to the Japanese market. We look forward to making this product available to Japanese customers together with our distribution partner for Orsiro, Japan Lifeline," said Jeffrey Annis, Managing Director of BIOTRONIK Japan.
1 Target vessel failure: Defined as any clinically-driven revascularization of the target vessel (TVR), target vessel Q-wave or non-Q-wave yocardial infarction (MI), or cardiac death.
2 Pilgrim T. et al. Lancet. 2014, 384 (9960).
3 Caution: Orsiro DES is an investigational device in Japan
At BIOTRONIK, patient well-being is our top priority and has been for 60 years. BIOTRONIK is a leading global medical technology company with products and services that save and improve the lives of millions suffering from heart and blood vessel diseases. Driven by a purpose to perfectly match technology with the human body, we are dedicated innovators who develop trusted cardiovascular and endovascular solutions. BIOTRONIK is headquartered in Berlin, Germany, and is represented in over 100 countries.